ONCOmmunity

Effects of Rhenium(I)-diselenoether and of its Diselenide Ligand on the Production of Cathepsins B and S by MDA-MB231 Breast Malignant Cells.

By: Philippe Collery, Vijaykumar Veena, Didier Desmaële, Adhikesavan Harikrishnan, Basavegowda Lakshmi

Society for the Coordination of Therapeutic Research, Algajola, France; philippe.collery@gmail.com btveenavijaykumar@gmail.com veena.v@reva.edu.in.
2021-09-06; doi: 10.21873/anticanres.15418

Abstract

Background/aim

Rhenium(I)-diselenoether (Re-diSe) is a drug under development for the treatment of metastatic cancers, with selective inhibitory effects on MDA-MB231 cancer cells compared to normal HEK-293 cells, and with greater effects than its diselenide (di-Se) ligand. Rhenium (Re) compounds inhibit cathepsins, which are important proteolytic enzymes in cancer. This study investigated the effects of Re-diSe and di-Se on the production of cathepsins B and S in MDA-MB231 malignant and HEK-293 normal cells and their inhibitory effects following treatment with different doses for 72 h.

Materials

Elisa tests were used to assay the amount of cathepsins B and S in the medium of cultures.

Results

Re-diSe, but not diSe affected the viability of malignant cells and the expression of cathepsins B and S.

Conclusion

To the best of our knowledge, this is the first demonstration that Re-diSe may decrease the production of cathepsins B and S in cancer cells at doses as low as 10 μM.